Trevi Therapeutics (NASDAQ:TRVI) Announces Quarterly Earnings Results

Trevi Therapeutics (NASDAQ:TRVI) posted its quarterly earnings data on Tuesday. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.01, Zacks reports.

Trevi Therapeutics Trading Up 3.8 %

Shares of TRVI opened at $6.81 on Thursday. The firm has a fifty day moving average price of $4.50 and a 200-day moving average price of $3.71. The firm has a market capitalization of $523.46 million, a P/E ratio of -15.48 and a beta of 0.90. Trevi Therapeutics has a 12-month low of $2.30 and a 12-month high of $7.39.

Insider Activity at Trevi Therapeutics

In related news, insider Farrell Simon sold 81,313 shares of Trevi Therapeutics stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $6.75, for a total value of $548,862.75. Following the completion of the sale, the insider now directly owns 76,900 shares in the company, valued at $519,075. The trade was a 51.39 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 24.37% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have commented on TRVI shares. B. Riley reaffirmed a “buy” rating and set a $20.00 price objective (up from $11.00) on shares of Trevi Therapeutics in a research note on Wednesday. Oppenheimer lifted their price objective on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 11th. Raymond James raised shares of Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their price objective for the stock from $9.00 to $29.00 in a research note on Monday, March 10th. HC Wainwright reaffirmed a “buy” rating and set a $12.50 price objective on shares of Trevi Therapeutics in a research note on Wednesday. Finally, Needham & Company LLC lowered their target price on shares of Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research note on Wednesday. Seven analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $17.56.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.